On 10 October 2012, orphan designation (EU/3/12/1049) was granted by the European Commission to Clovis Oncology UK Limited, United Kingdom, for rucaparib for the treatment of ovarian cancer.
Rucaparib has been authorised in the EU as Rubraca since 24 May 2018.
|Disease / condition||
Treatment of ovarian cancer
|Date of decision||
|Orphan decision number||
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Rubraca at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the orphan medicine assessment report .
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.